Compare
Nexalin Technology, Inc. vs Positron Corp vs iTonic Holdings Ltd vs Guided Therapeutics Inc
| Latest fiscal year | Nexalin Technology, Inc. NXL | Positron Corp POSC | iTonic Holdings Ltd ITOC | Guided Therapeutics Inc GTHP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $301.6K | $461.5K | $523.0K | $767.0K |
| Revenue growth (YoY) | +78.8% | -21.5% | +16.7% | n/m |
| Gross margin | 79.7% | -458.2% | 62.6% | 74.4% |
| Operating margin | n/m | n/m | -991.7% | -309.3% |
| Net margin | n/m | n/m | -974.7% | -416.7% |
| Net income | -$8.22M | -$10.60M | -$5.10M | -$3.20M |
| EPS (Diluted) | -$0.50 | -$0.34 | -$0.32 | -$0.04 |
| Operating cash flow | -$4.96M | -$4.70M | -$3.23M | -$1.07M |
| Free cash flow | n/a | n/a | -$3.24M | -$1.07M |
| Cash & equivalents | $654.8K | n/a | $1.49M | n/a |
| Total assets | $4.64M | $4.00M | $9.10M | $1.32M |
| Total liabilities | $887.3K | $2.56M | $969.8K | $7.33M |
| Shareholders' equity | $3.75M | $1.44M | $6.12M | -$6.01M |
| Return on year-end equity | -219.4% | -734.4% | -83.3% | n/a |
| Shares outstanding | 19.19M | 32.80M | n/a | 86.15M |
Revenue, most recent five fiscal years
| Fiscal year | Nexalin Technology, Inc. | Positron Corp | iTonic Holdings Ltd | Guided Therapeutics Inc |
|---|---|---|---|---|
| Latest | $301.6K Ended 2025-12-31 | $461.5K Ended 2025-12-31 | $523.0K Ended 2025-12-31 | $767.0K Ended 2025-12-31 |
| 1 year earlier | $168.7K Ended 2024-12-31 | $587.5K Ended 2024-12-31 | $448.2K Ended 2024-12-31 | $7.0K Ended 2024-12-31 |
| 2 years earlier | $110.7K Ended 2023-12-31 | n/a | $628.6K Ended 2023-12-31 | $98.0K Ended 2023-12-31 |
| 3 years earlier | $1.32M Ended 2022-12-31 | n/a | $679.8K Ended 2022-12-31 | $13.0K Ended 2022-12-31 |
| 4 years earlier | $144.1K Ended 2021-12-31 | n/a | n/a | $81.0K Ended 2021-12-31 |